Inhaled Corticosteroids Increase Diabetes Mellitus Risk According to New Study Published in The American Journal of Medicine
New York, NY, December 14, 2010 – Inhaled corticosteroids are widely used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). However, these drugs may be associated with diabetes development and progression. In a study published in the most recent issue of The American Journal of Medicine, researchers found that inhaled corticosteroids were associated with a 34% increase in the rate of diabetes onset and in the rate of diabetes progression. At the highest inhaled doses the risk increased by 64% in diabetes onset and 54% in diabetes progression.
Although inhaled corticosteroids are recommended only for patients with the most severe COPD, current practice has led to their use in less severe cases. In fact, over 70% of all patients with COPD are using inhaled corticosteroids. Since COPD and diabetes tend to increase with age, it is particularly important to assess any possible interaction between inhaled corticosteroid use and deterioration in glycemic control.
Investigators from McGill University and the Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, used data from over 380,000 patients treated for respiratory diseases identified in the Quebec health insurance databases. 30,167 patients developed diabetes during 5 ½ years of follow-up and another 2099 who progressed from oral hypoglycemic treatment to insulin.
Lead investigator Samy Suissa, PhD, Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada, and the Department of Epidemiology and Biostatistics and Department of Medicine, McGill University, observed that “high doses of inhaled corticosteroids commonly used in patients with COPD are associated with an increase in the risk of requiring treatment for diabetes and of having to intensify therapy to include insulin. Therefore, patients instituting therapy with high doses of inhaled corticosteroids should be assessed for possible hyperglycemia and treatment with high doses of inhaled corticosteroids limited to situations where the benefit is clear.”
This large cohort allowed the accurate estimation of relative risk. There have been other major randomized trials that have not shown a significant association of inhaled corticosteroids and diabetes onset. In this study, the authors found an incidence of diabetes onset of 14.2 per 1000 patients per year. At that rate, previous studies may not have had sufficient data to detect the excess risk. “These are not insubstantial numbers,” commented Dr. Suissa. “Over a large population the absolute numbers of affected people are significant.”
The article is “Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression” by Samy Suissa, PhD, Abbas Kezouh, PhD, Pierre Ernst, MD, MSc. It appears in The American Journal of Medicine, Volume 123, Issue 11 (November 2010) published by Elsevier.
# # #
Full text of the article is available upon request. Contact Pamela Poppalardo at 732-238-3628 or firstname.lastname@example.org to obtain a copy. To schedule an interview with Dr. Samy Suissa contact Mark Shainblum, Research Communications Officer, Jewish General Hospital, Lady Davis Institute for Medical Research, 514-340-8222 x 6592, mshainblum@jgh,mcgill.ca.
About the American Journal of Medicine
The American Journal of Medicine (http://www.amjmed.com), known as the “Green Journal,” is one of the oldest and most prestigious general internal medicine journals published in the United States. It has an Impact Factor of 4.466, which ranks it 14 out of 133 General and Internal Medicine titles according to the Journal Citation Reports® 2009 published by Thomson Reuters.
AJM, the official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus U.S. medical schools, publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in The American Journal of Medicine is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. AJM is published by Elsevier.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com